Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma

被引：116

作者：

Sahara, N

Takeshita, A

Shigeno, K

Fujisawa, S

Takeshita, K

Naito, K

Ihara, M

Ono, T

Tamashima, S

Nara, K

Ohnishi, K

Ohno, R

机构：

[1] Hamamatsu Univ Sch Med, Lab Med, Hamamatsu, Shizuoka 4313192, Japan

[2] Seirei Hamamatsu Gen Hosp, Div Haematol, Hamamatsu, Shizuoka, Japan

[3] Seirei Mikatabara Hosp, Div Internal Med, Shizuoka, Japan

[4] Aichi Canc Ctr, Nagoya, Aichi 464, Japan

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 117卷 / 04期

关键词：

multiple myeloma; CD56; plasmablast; flow cytometry; prognosis;

D O I：

10.1046/j.1365-2141.2002.03513.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We analysed CD56 expression in 70 patients with multiple myeloma (MM) to determine its clinicopathological and prognostic significance. Fifty-five (79%) patients were CD56(+) . CD56(-) patients (n = 15) had higher beta(2) microglobulin levels and a higher incidence of extramedullary disease, Bence Jones protein, renal insufficiency and thrombocytopenia than CD56(+) patients. Their myelomas more frequently had a plasmablastic morphology. Overall survival was significantly lower in CD56(-) than CD56(+) patients (22 vs 63 months, P = 0.0002). We conclude that CD56(-) MM is a discrete entity associated with more aggressive disease. The higher incidence of plasmablastic cases suggested that CD56(-) MM may develop from a less mature plasma cell than CD56(+) MM.

引用

页码：882 / 885

页数：4

共 10 条

[1]

DURIE BGM, 1986, SEMIN ONCOL, V13, P300

[2]

DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO

[3]

2-U

[4] Plasmablastic morphology - An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group [J].

Greipp, PR ;

Leong, T ;

Bennett, JM ;

Gaillard, JP ;

Klein, B ;

Stewart, JA ;

Oken, MM ;

Kay, NE ;

Van Ness, B ;

Kyle, RA .

BLOOD, 1998, 91 (07) :2501-2507

[5]

GREIPP PR, 1985, BLOOD, V65, P305

[6]

HARADA H, 1993, BLOOD, V81, P2658

[7] CLINICOPATHOLOGICAL CORRELATES OF CD56 EXPRESSION IN MULTIPLE-MYELOMA - A UNIQUE ENTITY [J].

MATHEW, P ;

AHMANN, GJ ;

WITZIG, TE ;

ROCHE, PC ;

KYLE, RA ;

GREIPP, PR .

BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (02) :459-461

[8] The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma [J].

Pellat-Deceunynck, C ;

Barillé, S ;

Jego, G ;

Puthier, D ;

Robillard, N ;

Pineau, D ;

Rapp, MJ ;

Harousseau, JL ;

Amiot, M ;

Bataille, R .

LEUKEMIA, 1998, 12 (12) :1977-1982

[9] Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression [J].

Rawstron, A ;

Barrans, S ;

Blythe, D ;

Davies, F ;

English, A ;

Pratt, G ;

Child, A ;

Morgan, G ;

Jack, A .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (01) :138-143

[10]

VANCAMP B, 1990, BLOOD, V76, P377

← 1 →